Kisqali

Kisqali (ribociclib) is a targeted medicine used to treat hormone receptor-positive (HR+), HER2-negative [HR+ HER2-] breast cancer, specifically for early-stage (high-risk) or advanced/metastatic cases. It is taken in combination with endocrine therapy (aromatase inhibitors or fulvestrant) to block cancer cell growth.